Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ACHV Achieve Life
4.860+0.010+0.21%
Close
01/31 16:00 ET
High
5.010
Open
4.875
Turnover
262.81K
Low
4.790
Pre Close
4.850
Volume
53.58K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Alpha Teknova (NASDAQ:TKNO) Versus Achieve Life Sciences (NASDAQ:ACHV) Head-To-Head Contrast
Alpha Teknova (NASDAQ:TKNO – Get Rating) and Achieve Life Sciences (NASDAQ:ACHV – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies
Achieve Life Sciences Management to Meet Virtually With Lake Street
12 Health Care Stocks Moving In Monday's After-Market Session
GainersAxcella Health (NASDAQ:AXLA) shares moved upwards by 49.9% to $0.65 during Monday's after-market session. Today's trading volume for this security ended up closing at 1.2 million shares, which
Achieve Life Sciences Holder Dialectic to Engage 'More Actively'
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Short Interest Up 12.0% in December
Achieve Life Sciences, Inc. (NASDAQ:ACHV – Get Rating) saw a large increase in short interest in the month of December. As of December 30th, there was short interest totalling 852,900 shares, an inc
Achieve Life Sciences Stock Rises on Top Shareholder's Engagement Plans
By Sabela Ojea Shares of Achieve Life Sciences Inc. on Thursday climbed 5.9% to $4.50 after its top shareholder said it plans to be more involved in the company. The biotech company said Dialectical
Biotech Alert: Searches Spiking for These Stocks Today
Maxim Group Reaffirms Their Buy Rating on Achieve Life Sciences (ACHV)
Oppenheimer Adjusts Achieve Life Sciences Price Target to $17 From $20, Maintains Outperform Rating
09:04 AM EST, 01/10/2023 (MT Newswires) -- Achieve Life Sciences (ACHV) has an average rating of Buy and price targets ranging from $8 to $47, according to analysts polled by Capital IQ. (MT Newswires
Achieve Life Sciences (ACHV) Gets a Buy From H.C. Wainwright
Company Overview
More
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor. The company was founded in October 1991 and is headquartered in Vancouver, Canada.
CEO： Mr. John Bencich
Market： NASDAQ
Listing Date： 10/11/1995
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet